Emma L O'Dowd1, Maruti Kumaran2, Sadia Anwar2, Begoña Palomo3, David R Baldwin2. 1. Division of Public Health and Epidemiology, Clinical Sciences Building, Nottingham City Campus, Hucknall Road, Nottingham NG5 1PB, United Kingdom. Electronic address: emma.o'dowd@nottingham.ac.uk. 2. Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, United Kingdom. 3. Department of Respiratory Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
Abstract
OBJECTIVES: There is a lack of good quality evidence or a clear consensus of opinion internationally regarding who should receive preoperative imaging of the brain prior to radical treatment for non-small cell lung cancer (NSCLC). We aimed to establish the proportion of patients who developed brain metastases following curative surgery and to estimate how many could have been detected by preoperative magnetic resonance imaging (MR). METHODS: We performed a retrospective analysis of 646 patients who underwent surgery for lung cancer with curative intent at a regional thoracic surgical centre in the United Kingdom. We identified those who developed brain metastases in the postoperative period and, by using volume doubling times, estimated the size of the metastasis at the time of surgery. We then determined the proportion of metastases that would have been seen on preoperative MR brain at detection thresholds of 2 and 5mm diameter. RESULTS: There was a 6.3% incidence of postoperative brain metastases, with the majority occurring within 12 months of surgery. Those who developed metastases were more likely to have adenocarcinoma and the majority had early stage malignancy (73% stage I or stage II). We estimate that 71% of those who developed cerebral metastases might have been detected had they undergone MR brain as part of their staging (4.4% of all patients). CONCLUSION: Based on our findings we suggest that, in addition to standard staging investigations, patients have brain imaging (MR or equivalent) prior to curative surgery in NSCLC regardless of preoperative stage.
OBJECTIVES: There is a lack of good quality evidence or a clear consensus of opinion internationally regarding who should receive preoperative imaging of the brain prior to radical treatment for non-small cell lung cancer (NSCLC). We aimed to establish the proportion of patients who developed brain metastases following curative surgery and to estimate how many could have been detected by preoperative magnetic resonance imaging (MR). METHODS: We performed a retrospective analysis of 646 patients who underwent surgery for lung cancer with curative intent at a regional thoracic surgical centre in the United Kingdom. We identified those who developed brain metastases in the postoperative period and, by using volume doubling times, estimated the size of the metastasis at the time of surgery. We then determined the proportion of metastases that would have been seen on preoperative MR brain at detection thresholds of 2 and 5mm diameter. RESULTS: There was a 6.3% incidence of postoperative brain metastases, with the majority occurring within 12 months of surgery. Those who developed metastases were more likely to have adenocarcinoma and the majority had early stage malignancy (73% stage I or stage II). We estimate that 71% of those who developed cerebral metastases might have been detected had they undergone MR brain as part of their staging (4.4% of all patients). CONCLUSION: Based on our findings we suggest that, in addition to standard staging investigations, patients have brain imaging (MR or equivalent) prior to curative surgery in NSCLC regardless of preoperative stage.
Authors: Luis Filipe Azenha; Pietro Bertoglio; Peter Kestenholz; Michel Gonzalez; Matyas Pal; Thorsten Krueger; Bassam Redwan; Volkan Koesek; Eyad Al Masri; Takuro Miyazaki; Farahnaz Sadegh Beigee; Benedetta Bedetti; Philipp Schnorr; Joachim Schmidt; Patrick Zardo; Laura Boschetti; Sven Oliver Schumann; Fabrizio Minervini Journal: Cancers (Basel) Date: 2022-05-13 Impact factor: 6.575
Authors: Priscila H Goncalves; Stephanie L Peterson; Fawn D Vigneau; Ronald D Shore; William O Quarshie; Khairul Islam; Ann G Schwartz; Antoinette J Wozniak; Shirish M Gadgeel Journal: Cancer Date: 2016-04-08 Impact factor: 6.860
Authors: Anna Maria Di Giacomo; Monica Valente; Alfonso Cerase; Maria Fortunata Lofiego; Francesca Piazzini; Luana Calabrò; Elisabetta Gambale; Alessia Covre; Michele Maio Journal: J Exp Clin Cancer Res Date: 2019-10-17